



---

## **Bill Mezzanotte MD**

**Chief Medical Officer & Executive  
Vice President, Head of R&D**  
CSL Behring

**Bill Mezzanotte, MD** was appointed Head of Research and Development in October 2018 and Chief Medical Officer was added to his direct responsibilities in 2020. Bill is responsible for developing and executing CSL's Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success.

In April 2017, Bill joined the company as Head of Clinical Development, responsible for clinical science, statistics and clinical operations across CSL Behring's portfolio. Most recently he served as Senior Vice President and Head of Development, where he oversaw regulatory, project management, clinical science & operations, plasma, recombinant protein and gene therapy pharmaceutical development activities worldwide.

Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas.

In 2020, Bill was named to the Board of Directors of the Philadelphia-based University City Science Center.

Bill obtained his M.D. at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University. He is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine and currently serves as a member of the Board of Directors of the Philadelphia-based University City Science Center.



---

## **Dr Andrew Nash**

**Chief Scientific Officer &  
Senior Vice President Research**  
CSL Behring

**Andrew Nash, PhD** is the Chief Scientific Officer and Senior Vice President, Research at CSL Behring and is an Honorary Associate Professor at the University of Melbourne. He completed his PhD in immunology at The University of Melbourne in 1988 and, after moving to the Centre for Animal Biotechnology in the Faculty of Veterinary Science, developed and led a research group focused on basic and applied aspects of cytokine biology.

In 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics (then Amrad Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006. Following the acquisition he was appointed as CSL's SVP, Research and is currently based at the Bio21 Institute where he leads a large global effort focused on the discovery and development of new protein, cell and gene-based medicines to treat serious human disease.



---

## **Mittie Doyle MD**

**Vice President, R&D Immunology**  
CSL Behring

**Mittie Doyle, MD, FACP** joined CSL Behring in 2017 and currently serves as Vice President and Clinical Co-Lead overseeing Immunology Clinical and Therapeutic Strategy. Mittie earned her M.D. at Yale School of Medicine, completed her Internal Medicine training at Massachusetts General Hospital and her Rheumatology fellowship at Brigham and Women's Hospital. She is a board-certified rheumatologist with over 25 years of experience in both academic medicine and the pharmaceutical industry. She previously served on the faculties of Harvard and Tulane Medical School and the adjunct faculty at the University of Pennsylvania Medical School.

Her clinical development expertise spans first in human clinical trials and proof of concept through successful Biologics License Application (BLA) submissions. She began her industry career at Centocor/Janssen supporting numerous large molecule programs including Remicade® and Simponi®. She also led the Stelara® psoriatic arthritis program. Following her tenure at Janssen, she gained experience at two smaller biotech companies; first in the Early Development / Translational Medicine group at Alexion as a Senior Medical Director in complement biology and then as Vice President of Clinical Research and Development at Flexion Therapeutics for the Zilretta® program. Prior to joining CSL Behring she served as Vice President, Global Development Team Leader in Immunology at Shire.

In addition to her strong background in Immunology, Mittie brings extensive experience in orphan drug development, indication selection, corporate strategy and business development to her role at CSL Behring.



---

## **Bill Campbell**

**Executive Vice President & Chief  
Commercial Officer**

CSL Behring

**Bill Campbell** was appointed as Executive Vice President & Chief Commercial Officer on July 1, 2017. Bill has responsibility for a variety of global functions including Sales, Marketing, Commercial Development, Medical Affairs, Analytics and Public Policy. Bill is accountable for our global Commercial strategy and leads a team of 1,800 Commercial professionals around the world.

Prior to being appointed to his current role, Bill led CSL Behring's North American Commercial Operations. Bill and his team were responsible for the successful launches of IDELVION<sup>®</sup>, AFSTYLA<sup>®</sup>, HAEGARDA<sup>®</sup> and other new products. Under Bill's leadership, the North American region delivered substantial revenue and volume growth across the portfolio.

Bill has more than 35 years of diverse Pharmaceutical and Biotechnology experience across a range of therapeutic areas, including Oncology, Women's Health, Vaccines, and Plasma Proteins. He has served in a number of progressive senior leadership roles with Wyeth, Abbott, Teva, Cephalon and Centeon, a CSL predecessor company.

In addition to Bill's industry experience, he has previously served on the Board of Directors for the National Kidney Foundation Delaware Valley, the Plasma Protein Therapeutic Association (PPTA) and the Biotechnology Innovation Organization (BIO).



---

## **Laurie Lee MD**

**Vice President, R&D Transplant**  
CSL Behring

**Laurie Lee, MD** joined CSL Behring in 2020 and currently serves as Vice President and Clinical Co-Lead overseeing Transplant Clinical and Therapeutic Strategy.

Laurie completed her undergraduate studies at the University of Notre Dame and earned her medical degree from The Ohio State University College of Medicine. She trained in Pediatrics at Columbus Children's Hospital, Allergy and Immunology at Duke University and maintains board certification in both. She has over 20 years' experience in both academic medicine and the pharmaceutical industry. She previously held a faculty position at Duke University for over a decade where her clinical research centered on thymic output following bone marrow transplantation for severe combined immune deficiency (SCID) in the neonatal period. She also served as Associate Director of the Allergy and Immunology Training program.

Her industry experiences cross all phases of development, from pre-clinical to post-marketing studies and medical affairs at GSK. The majority of her clinical development has been in the Respiratory area including work with a novel immunomodulatory molecule for allergic asthma. She also has experience in rare diseases with the Marketing Authorisation Application (MAA) for Strimvelis, the first ex-vivo gene therapy product for children with adenosine deaminase (ADA) deficient SCID. Most recently she led the Phase III program and the global submissions for an inhaled triple therapy, Trelegy, in asthma.